TSI-Test-Email #3-He Sees Unicorns. Unicorn Returns.

%%First Name|Friend%%,

Kevin O’Leary and psychedelic drugs? Talk about strange bedfellows.

For those who don’t know him, Kevin O’Leary is a Canadian market analyst, TV pundit, and passionate investor. Perhaps O’Leary is best known as a panelist on the Canadian business startups show “Dragon’s Den”.

Today, Kevin O’Leary is a major investor in and bullish proponent for psychedelic drugs.

O’Leary makes no attempt to hide his conservative inclinations. This comes out loud-and-clear when O’Leary recently interviewed JR Rahn, former Uber executive and now CEO of MindMed Inc (CAN:MMED / US:MMEDF).

O’Leary:

“…when I was first approached by one of your board members over a year ago to get involved in MindMed I said absolutely no way. I don’t want anything to do with recreational drugs. I never got invested in cannabis for that reason it’s a Schedule one narcotic — still is federally [in the United States].”

No, to cannabis. Yes, to psychedelic drugs – as an investment opportunity. Why?

O’Leary says:

“It has the potential to become ground-breaking medicine…Research that actually started in the early 60s was shut down because a lot of the psychedelics became illegal. But now the promise of perhaps fixing huge problems like drug addiction, opioid addiction, alcoholism, depression, ADD, all of these metrics.”

This conservative investor put aside his biases against these drugs (for recreational use) and saw:
– A huge need.
– Large treatment markets.
– Poor existing treatment options.
– Spectacular results in clinical trials with psychedelic drugs.

Mental health services is a $225 billion treatment market in the United States alone, according to Statista.

Kevin O’Leary is not some do-gooder out to change the world. He wants to make money – and the more the better.

Psychedelic drugs do have the potential to change the world, providing effective treatment options for mental health disorders that afflict more than 1 billion people. O’Leary has nothing against that.

But when Kevin O’Leary looks at psychedelic drugs, he doesn’t see a better world full of happier people.

He sees unicorns. Unicorn returns

Kevin O’Leary won’t touch cannabis as an investment…

…but he loves the potential of psychedelic drugs. Why?

Large markets + disruptive solutions = unicorn size returns (a unicorn has a market value of $1B+).

CLICK HERE FOR 6 REASONS TO INVEST IN PSYCHEDELICS:

Latest posts